We're working to build more solutions for conditions of the microbiome - from #IBS and ##SIBO to PCOS and #Diabetes. How can you help? .

Excited to see our research highlighted by @CedarsSinai Newsroom ahead of #ENDO2025! 🎉 @TheEndoSociety . Dr. Margaret Wei, Cedars Sinai fellow and collaborator w/ MAST, will be presenting an oral tomorrow on our latest findings linking hypothyroidism & SIBO- a compelling step

📣 The MAST Program is proud to be presenting 3 posters & 1 oral at #ENDO2025 this weekend! @TheEndoSociety . From SIBO and hypothyroidism to metabolic impacts of gut microbes, our team is exploring how GI health and the endocrine system are deeply connected through the

💭Newest MAST paper!.Our latest research shows that breath gas profiles are influenced, at least in part, by small bowel microbial composition 😮‍💨 🤝🦠. 📈Higher breath H₂S is linked to H₂S-producing bacteria & is associated with looser stools.💨 Elevated CH₄ is associated with

What does #WorldMicrobiomeDay mean to those of us at MAST? Let’s find out! 👇. Overall, today is a great chance to spread awareness on the small bowel microbiome & how it impacts different aspects of health and disease. Visit our website to catch up on the latest!

RT @MarkPimentelMD: Paper out! Methane and Hydrogen sulfide on three-gas breath test correlate with methanogens and H2S producers in the SM….

Most #IBS drug studies focus on what works. But what about harm?. We analyzed 54 clinical trials to calculate number needed to harm (NNH) for common IBS meds. 🔍 Key:.- Rifaximin=safest.- Tricyclics, alosetron, tenapanor=highest risk.- NNH + NNT=better patient-centered decisions

Some Wednesday Wisdom from #DDW2025! . Throwing it back to MAST's @MarkPimentelMD closing out his ‘SIBO: Hype or Hip?’ presentation with a powerful reminder: #SIBO is real and there is ✨HOPE✨ in the progress being made through research to understand, diagnose, and treat it

Artificial sweeteners aren’t just in your snacks anymore… they’re in your vape. A @nourishbywebmd article investigates neotame, a next-gen sweetener found in many disposable e-cigarettes & ultra-processed foods. MAST physician-scientist @RuchiMathurMD weighs in on the growing

Today we celebrated an emotional (and fun!) farewell as we sent off Mo, Sepideh, and Dilara on their next big adventures- residency and medical school! Wishing you all the success in this next chapter of your careers. Once a MASTer, always a MASTer! 🫶

RT @MarkPimentelMD: In this study, we examine the safety of drugs for #IBS. It turns out that tricyclic antidepressants are among the drugs….

Now in press‼️🚨📢 Adding to the dialogue, the newest evidence-based consensus on perioperative management for patients taking GLP-1 RAs informed by a systematic review of clinical outcomes and gastric emptying data. Proud to share that MAST endocrinologist @RuchiMathurMD was a

Presenting author, Maria Chus Villianueva-Millan, shares how CS-06 may be an important #microbiome therapy for the treatment of methane-associated constipation: Missed us @DDWMeeting? Head to our YouTube to watch poster summary videos, where our.

👩‍⚕️👨‍🔬 Happy #ClinicalTrialsDay! Today we celebrate the contributions of our REIMAGINE study subjects + those who have taken part in any of our clinical trials, as well as the dedicated clinical research team working behind the scenes!.Your commitment is helping us ✨reimagine✨

This #NationalHospitalWeek, we’re proud to recognize the incredible hospital workers @CedarsSinai. At MAST, we’re honored to advance microbiome research that improves patient care. Here’s to the dedication and innovation that drive our hospital community every day!! 💙🏥

MAST research shows that low-dose rifaximin + N-acetylcysteine (NAC) outperforms rifaximin alone in treating IBS-D, leading to ⬆️symptom relief. Could this combination therapy be the future of IBS-D management?  We will know soon…. A phase 2b clinical trial is about to be

What an incredible couple of days at #DDW2025 with the best team!.With so many posters, talks, and everything in between, here are just a few other standout moments:.➡️ Dr. Pimentel’s oral on low-dose rifaximin + NAC for IBS-D treatment.➡️  Dr. Germano’s oral on a palatable

RT @MarkPimentelMD: 2/2.4. Transcriptomics shows the damaging effects of #SIBO, #IMO and mostly #ISO (hydrogen sulfide) on the small intest….

RT @MarkPimentelMD: Summary of @MASTprogram work at #DDW2025.1. Low dose rifaximin+NAC better than rifaximin in #IBS-D. Hydrogen sulfide is….